| Methods | Randomised controlled double‐blind trial. | |
| Participants | 8 patients with CMT1A carrying the duplication on chromosome 17p11.2 harbouring the PMP22 gene. | |
| Interventions | One group 50 µg/ kg 3x/w recombinant human NT‐3 subcutaneously. Control group placebo injections for 6 months. | |
| Outcomes | Nerve biopsies, Neuropathy impairment scale, pegboard test, density of myelinated fibers and Schwann cells in sural nerve biopsies. | |
| Notes | No drop outs | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment? | Low risk | A ‐ Adequate |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.